Does NPNR include a finished nasal-spray device?

The standard material is supplied as an EV raw-material presentation. Device selection, excipient compatibility and spray-performance studies can be discussed as a separate development project.

How should NPNR be stored?

The current presentation is cryopreserved and should be stored at the recommended frozen condition, with dry-ice shipment and avoidance of unnecessary freeze-thaw cycles.

Is NPNR an approved therapy for neurological disease?

No. It is an investigational research and development material and is not represented as an approved diagnostic or therapeutic product.

GoldenExo® NPNR

A low-volume, cryopreserved UC-MSC extracellular vesicle material developed for intranasal formulation studies and translational research involving neural repair, neuroinflammatory signaling and nose-to-brain delivery feasibility.

Quick Facts

MSC-EV Material for Intranasal Research
Particle Content: 2.4E10 particles
Presentation: Cryopreserved / 1 mL
Storage: Recommended at -80°C
Shipping: Dry ice
Research Route: Intranasal
COA
TDS
Intranasal Formulation
Delivery Compatibility

A concentrated EV starting material for intranasal formulation, device compatibility and neural-microenvironment studies.

NPNR combines a low-volume concentrated presentation with a native MSC-EV signal base for nasal formulation, device compatibility, neuroinflammatory balance and delivery-route feasibility research.

Low-Volume Presentation: A concentrated 1 mL format designed for intranasal formulation and device-compatibility studies.

Native MSC-EV Signaling: Retains a broad EV cargo profile for research into neuroinflammatory balance and neural microenvironment support.

Route-Development Flexibility: Supports dose, viscosity, osmolality, spray-device and nasal-retention feasibility assessment.

Translational Support: Can be paired with analytical characterization, biodistribution research and project-specific formulation work.

Evaluation pathway designed around product use

01 Source & Cell Bank: Confirm source, cell identity and batch traceability.

02 Culture & Harvest: Control culture system and harvest window by product positioning.

03 Purification & Concentration: Match purification strategy to lyophilized, frozen or formulation-development needs.

04 Fill & Storage: Define specification, packaging and shipping conditions.

05 Quality Evaluation: Combine EV identity, purity, safety and functional tests by project.

06 Application Support: Connect to formulation, delivery, model validation and co-development.

Quality Evaluation Around Route and Application Model

Source Identity & Traceability: Documented human UC-MSC or defined producer-cell sourcing; Cell-bank identity and batch records; Project-appropriate traceability and source controls

Controlled Manufacturing: Defined culture, harvest and purification workflows; Lyophilized or cryopreserved presentation by product design; Batch consistency and scale-up compatibility

Orthogonal Quality Evaluation: Particle concentration, size and EV identity; Purity, membrane integrity and safety tests; Functional or stability assays selected by project

Batch-Level Documentation: COA, TDS and SDS supplied by project scope; Connection to formulation development and further manufacturing; Support for technical review and collaboration planning

Product-specific analytical focus: Route-specific development may include particle characterization, sterility, endotoxin, pH, osmolality, membrane integrity, marker positivity and device-delivery compatibility.

Where the Product Can Fit

Intranasal Delivery Feasibility: Evaluate administration volume, device compatibility and repeat-dose research protocols.

Neuroinflammatory Signaling: Study EV-mediated regulation of inflammatory pathways relevant to neural microenvironments.

Neural Repair Research: Explore neurite, glial-support and tissue-recovery related biological responses.

Biodistribution Strategy: Support labeled-EV tracing and nose-to-brain delivery research when incorporated into a study plan.

Key Information for Technical Evaluation

Product Name: GoldenExo® NPNR

Material Type: Concentrated UC-MSC-derived extracellular vesicles / exosomes

Particle Content: 2.4E10 particles

Presentation: Cryopreserved / 1 mL

Storage: Recommended at -80°C

Shipping: Dry ice

Research Route: Intranasal delivery, nose-to-brain feasibility and neural-microenvironment research

Collaboration: Formulation compatibility, device evaluation, tracing and functional model co-development

Storage, freeze-thaw, delivery-device and formulation-compatibility requirements should follow the batch TDS, COA and confirmed project documentation.

From Product Supply to Co-Development

Standard Material Supply: Deliver material and agreed documentation according to product specification.

Formulation & Delivery Development: Evaluate concentration, excipients, packaging and application format.

Quality & Stability Research: Extend analytics, stability and model validation by project.

OEM / ODM / CDMO: Connect raw material, prototype and further manufacturing collaboration.

FAQ

What is GoldenExo® NPNR?: NPNR is a concentrated cryopreserved UC-MSC extracellular vesicle material developed for intranasal formulation and neuroscience research.
Does NPNR include a finished nasal-spray device?: The standard material is supplied as an EV raw-material presentation. Device selection, excipient compatibility and spray-performance studies can be discussed as a separate development project.
How should NPNR be stored?: The current presentation is cryopreserved and should be stored at the recommended frozen condition, with dry-ice shipment and avoidance of unnecessary freeze-thaw cycles.
Is NPNR an approved therapy for neurological disease?: No. It is an investigational research and development material and is not represented as an approved diagnostic or therapeutic product.